CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 232 enrolled
Drug / intervention
hydrochlorothiazide +1 moredrug
Likely dose
hydrochlorothiazide 50mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01647932
NCT01647932Phase 3Completed
CompareCT.gov

Safety and Efficacy of the Combination of Loop Diuretics With Thiazide-type Diuretics in Patients With Decompensated Heart Failure: a Double-blind, Randomized, Placebo-controlled Trial (CLOROTIC Trial).

Spanish Society of Internal Medicine·interventional·Posted Jul 24, 2012·Updated Oct 4, 2022

In Brief

A Phase 3 clinical trial evaluating hydrochlorothiazide and Placebo for Heart Failure. Completed, enrolled 232 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether a combined diuretic therapy (loop diuretics with thiazide-type diuretics) is more effective (in terms of improving fluid overload symptoms) among patients with decompensated heart failure in comparison with loop diuretic alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesSpain
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 24, 2012
Enrollment StartOct 1, 2014
Primary CompletionDec 15, 2019
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 13.9 years ago

Interventions

hydrochlorothiazidedrug

hydrochlorothiazide according to clearance of creatinine; \>50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.

Placebodrug

Placebo according to clearance of creatinine; \>50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd \<20ml/min 2 pills daily.